BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loebermann M, Fritzsche C, Geerdes-Fenge H, Heijnen E, Kirby D, Reisinger EC. A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults. Infection 2019;47:105-9. [PMID: 30298473 DOI: 10.1007/s15010-018-1233-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Jordan K, Murchu EO, Comber L, Hawkshaw S, Marshall L, O'Neill M, Teljeur C, Harrington P, Carnahan A, Pérez-Martín JJ, Robertson AH, Johansen K, Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O, Ryan M. Systematic review of the efficacy, effectiveness and safety of cell-based seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Rev Med Virol 2022;:e2332. [PMID: 35137512 DOI: 10.1002/rmv.2332] [Reference Citation Analysis]
2 . Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2021-2022. Can Commun Dis Rep 2021;47:372-80. [PMID: 34650334 DOI: 10.14745/ccdr.v47i09a04] [Reference Citation Analysis]
3 Sinilaite A, Gemmill I, Harrison R. Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines. Can Commun Dis Rep 2020;46:324-32. [PMID: 33316000 DOI: 10.14745/ccdr.v46i10a03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Pawelec G, McElhaney J. Recent advances in influenza vaccines. F1000Res 2020;9:F1000 Faculty Rev-305. [PMID: 32399192 DOI: 10.12688/f1000research.22611.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Bühler S, Ramharter M. Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures. ESMO Open 2019;4:e000481. [PMID: 30792907 DOI: 10.1136/esmoopen-2018-000481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]